Measles
Last Updated: 2019-08-27
ICD11: -
Last Updated: 2019-08-27
Author(s): Anzengruber F., Navarini A.
ICD11: -
Morbilli, first infectious disease.
After a measles infection has already occurred, a lifelong immunity exists.
Antipyretic measures, e.g:
Topical therapy
Vaccination against |
Category | Indication | Application notes |
Measles | S |
Persons born after 1970 ≥ 18 years old with unclear vaccination status, without vaccination or with only one vaccination in childhood |
Single vaccination with an MMR vaccine |
I |
When admission is imminent or when visiting a community institution (e.g. day care centre): Infants aged 9 months and over |
Double vaccination with one MMR/V-*vaccine If the first vaccination takes place at the age of 9 - 10 months, the 2nd MMR/V vaccination should already be given at the beginning of the 2nd year of life. |
|
I |
Born after 1970 from the age of 9 months with unclear vaccination status, without vaccination or with only one vaccination in childhood
exceptionally 6 - 8-month-old infants after individual risk-benefit analysis (off-label use) |
Single MMR(V)-**vaccination If necessary, complete in accordance with the recommendations applicable to the age group. If the first vaccination takes place at the age of 9 - 10 months, the 2nd MMR/V* vaccination should already be given at the beginning of the 2nd year of life. For first vaccination at the age of 6 - 8 months, a 2nd and 3rd MMR/V* vaccination should be given at the age of 11 - 14 and 15 - 23 months. * MMR/V = MMRV or MMR in co-administration with VZV vaccine ** MMR(V) = MMR with or without co-administration of VZV vaccine |
|
B |
Health services or care for immunodeficient or immunocompromised persons or persons working in community institutions: after 1970 Gebo-rene with unclear vaccination status, without vaccination or with only one vaccination in childhood. |
Single vaccination with an MMR vaccine |
S: Standard vaccinations with general use
I: Indication vaccinations for risk groups with individually (not occupational) increased exposure, disease or complication risk as well as for the protection of third parties
B: Vaccinations due to an increased occupational risk, e.g. after risk assessment in accordance with the Occupational Health and Safety Act/Biostuffs Ordinance/Ordinance on Occupational Health and Safety (ArbMedVV) and/or for the protection of third parties within the scope of the occupational activity
Robert Koch Institute, Epidemiological Bulletin No. 34. (2015).Rki.de.Retrieved 10 May 2016, from https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/34_15.pdf?__blob=publicationFile
Adverse side effects after MMR vaccination per 1 million vaccinated persons |
Complications of measles per 1 million measles sufferers |
|
Immunodeficiency | Very rare | All patients |
Ear infection |
0 | 70000-90000 |
Pneumonia | 0 | 10000-60000 |
Hospitalisation | 20-50 | 10000-25000 |
Febrile convulsions | 30-300 | 5000-7000 |
Brain inflammation | 0.6-1.6 | 200-2000 |
Platelet count | 30 | 330 |
Subacute sclerosing Panencephalitis (SSPE)* |
0 | 1-10 |
Allergic shock reaction (anaphylaxis) |
1-10 | 0 |
Autism | 0 | 0 |
Deaths |
< 1** | 300 bis 1000 |
Expenses |
1 million vaccinations cost 140 million francs. |
1 million patients cost between 3.6 and 5 billion Swiss francs. |
* The SSPE is a late consequence of a measles infection. Years after the infection, a creeping inflammation of the brain develops, which cannot be cured and is always fatal.
** No death is expected and no death due to the vaccine is known to date, but the risk cannot be completely ruled out.
Source: Federal Office of Public Health - Measles. (2016). Bag.admin.ch. Retrieved 10 May 2016, from http://www.bag.admin.ch/themen/medizin/00682/00684/01087/index.html lang=en